{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:28:47Z","timestamp":1792452527190,"version":"4.5.0"},"reference-count":299,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The field of inflammatory disease of the heart or \u201ccardio-immunology\u201d is rapidly evolving due to the wider use of non-invasive diagnostic tools able to detect and monitor myocardial inflammation. In acute myocarditis, recent data on the use of immunomodulating therapies have been reported both in the setting of systemic autoimmune disorders and in the setting of isolated forms, especially in patients with specific histology (e.g., eosinophilic myocarditis) or with an arrhythmicburden. A role for immunosuppressive therapies has been also shown in severe cases of coronavirus disease 2019 (COVID-19), a condition that can be associated with cardiac injury and acute myocarditis. Furthermore, ongoing clinical trials are assessing the role of high dosage methylprednisolone in the context of acute myocarditis complicated by heart failure or fulminant presentation or the role of anakinra to treat patients with acute myocarditis excluding patients with hemodynamically unstable conditions. In addition, the explosion of immune-mediated therapies in oncology has introduced new pathophysiological entities, such as immune-checkpoint inhibitor-associated myocarditis and new basic research models to understand the interaction between the cardiac and immune systems. Here we provide a broad overview of evolving areas in cardio-immunology. We summarize the use of new imaging tools in combination with endomyocardial biopsy and laboratory parameters such as high sensitivity troponin to monitor the response to immunomodulating therapies based on recent evidence and clinical experience. Concerning pericarditis, the normal composition of pericardial fluid has been recently elucidated, allowing to assess the actual presence of inflammation; indeed, normal pericardial fluid is rich in nucleated cells, protein, albumin, LDH, at levels consistent with inflammatory exudates in other biological fluids. Importantly, recent findings showed how innate immunity plays a pivotal role in the pathogenesis of recurrent pericarditis with raised C-reactive protein, with inflammasome and IL-1 overproduction as drivers for systemic inflammatory response. In the era of tailored medicine, anti-IL-1 agents such as anakinra and rilonacept have been demonstrated highly effective in patients with recurrent pericarditis associated with an inflammatory phenotype.<\/jats:p>","DOI":"10.3389\/fmed.2022.838564","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T01:47:47Z","timestamp":1646617667000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Immunomodulating Therapies in Acute Myocarditis and Recurrent\/Acute Pericarditis"],"prefix":"10.3389","volume":"9","author":[{"given":"Enrico","family":"Ammirati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Bizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Groh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Van de Heyning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Lehtonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pineton de Chambrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Picchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Brucato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e007405","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","article-title":"Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circulation Heart Fail."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jacep.2020.05.013","article-title":"Immunosuppressive therapy and risk stratification of patients with myocarditis presenting with ventricular arrhythmias","volume":"6","author":"Peretto","year":"2020","journal-title":"JACC Clin Electrophysiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1001\/jamacardio.2020.1096","article-title":"Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Inciardi","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/CIRCULATIONAHA.121.055913","article-title":"Myocarditis after BNT162b2 and mRNA-1273 vaccination","volume":"144","author":"Larson","year":"2021","journal-title":"Circulation."},{"key":"B5","doi-asserted-by":"publisher","first-page":"100774","DOI":"10.1016\/j.ijcha.2021.100774","article-title":"Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection","volume":"34","author":"Ammirati","year":"2021","journal-title":"Int J Cardiol Heart Vasc."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","author":"Patone","year":"2021","journal-title":"Nat Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1161\/CIRCULATIONAHA.121.056583","article-title":"Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults","volume":"145","author":"Truong","year":"2021","journal-title":"Circulation."},{"key":"B8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis with COVID-19 mRNA Vaccines","volume":"144","author":"Bozkurt","year":"2021","journal-title":"Circulation."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-021-27631-8","article-title":"Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database","volume":"13","author":"Nguyen","year":"2022","journal-title":"Nat Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jacc.2019.04.063","article-title":"Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction","volume":"74","author":"Ammirati","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.107.186093","article-title":"The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology","volume":"116","author":"Cooper","year":"2007","journal-title":"Circulation."},{"key":"B13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.tcm.2020.05.008","article-title":"Update on acute myocarditis","volume":"31","author":"Ammirati","year":"2020","journal-title":"Trends Cardiovasc Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and inflammatory cardiomyopathy: current evidence and future directions","volume":"18","author":"Tsch\u00f6pe","year":"2020","journal-title":"Nat Rev Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1056\/NEJMc0911362","article-title":"Human parvovirus B19-associated myocarditis","volume":"362","author":"Bock","year":"2010","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/S0735-1097(03)00648-X","article-title":"Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of myocarditis in children and adults","volume":"42","author":"Bowles","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijcard.2020.10.063","article-title":"Management perspectives from the 2019 Wuhan international workshop on fulminant myocarditis","volume":"324","author":"Veronese","year":"2021","journal-title":"Int J Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/ejhf.665","article-title":"Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature","volume":"18","author":"Verdonschot","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"B20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.110.958249","article-title":"Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure","volume":"4","author":"Stewart","year":"2011","journal-title":"Circ Heart Fail."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/ejhf.1738","article-title":"Viral genome search in myocardium of patients with fulminant myocarditis","volume":"22","author":"Veronese","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/CIRCRESAHA.115.306573","article-title":"Myocarditis","volume":"118","author":"Fung","year":"2016","journal-title":"Circ Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s000590050009","article-title":"Molecular pathology and structural features of enteroviral replication. Toward understanding the pathogenesis of viral heart disease","volume":"25","author":"Klingel","year":"2000","journal-title":"Herz."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1253\/circj.CJ-16-0234","article-title":"Clinical features of acute and fulminant myocarditis in children- 2nd nationwide survey by Japanese society of pediatric cardiology and cardiac surgery","volume":"80","author":"Matsuura","year":"2016","journal-title":"Circ J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/ejhf.2247","article-title":"Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab","volume":"23","author":"Ammirati","year":"2021","journal-title":"Eur J Heart Fail."},{"key":"B26","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jacc.2010.01.004","article-title":"Fulminant myocarditis associated with pandemic H1N1 influenza A virus in children","volume":"55","author":"Bratincs\u00e1k","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1126\/science.aav3487","article-title":"Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy","volume":"366","author":"Gil-Cruz","year":"2019","journal-title":"Science."},{"key":"B28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1084\/jem.20180722","article-title":"Self-reactive CD4(+) IL-3(+) T cells amplify autoimmune inflammation in myocarditis by inciting monocyte chemotaxis","volume":"216","author":"Anzai","year":"2019","journal-title":"J Exp Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/ejhf.1560","article-title":"Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence","volume":"21","author":"Tschope","year":"2019","journal-title":"Eur J Heart Fail."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/eurheartj\/ehp249","article-title":"Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study","volume":"30","author":"Frustaci","year":"2009","journal-title":"Eur Heart J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"Cd004471","DOI":"10.1002\/14651858.CD004471.pub3","article-title":"Corticosteroids for viral myocarditis","volume":"2013","author":"Chen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"102710","DOI":"10.1016\/j.autrev.2020.102710","article-title":"Efficacy of immunosuppressive therapy in myocarditis: A 30-year systematic review and meta analysis","volume":"20","author":"Cheng","year":"2021","journal-title":"Autoimmun Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1161\/CIR.0000000000000745","article-title":"Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association","volume":"141","author":"Kociol","year":"2020","journal-title":"Circulation."},{"key":"B34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1161\/01.CIR.89.1.252","article-title":"Gamma-globulin treatment of acute myocarditis in the pediatric population","volume":"89","author":"Drucker","year":"1994","journal-title":"Circulation."},{"key":"B35","doi-asserted-by":"publisher","first-page":"Cd004370","DOI":"10.1002\/14651858.CD004370.pub3","article-title":"Intravenous immunoglobulin for presumed viral myocarditis in children and adults","volume":"2015","author":"Robinson","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1056\/NEJM199508033330501","article-title":"A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators","volume":"333","author":"Mason","year":"1995","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41392-021-00700-6","article-title":"Impact of mechanical circulatory support and immunomodulation therapy on outcome of patients with fulminant myocarditis: Chinese registry of fulminant myocarditis","volume":"6","author":"Zhou","year":"2021","journal-title":"Signal Transduct Target Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00392-016-0986-9","article-title":"Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-\u03b2 treatment in patients with chronic viral cardiomyopathy","volume":"105","author":"Schultheiss","year":"2016","journal-title":"Clin Res Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMra0800028","article-title":"Myocarditis","volume":"360","author":"Cooper","year":"2009","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1161\/CIRCULATIONAHA.118.035319","article-title":"Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis","volume":"138","author":"Ammirati","year":"2018","journal-title":"Circulation."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s11739-021-02635-w","article-title":"Myocarditis in COVID-19 patients: current problems","volume":"16","author":"Mele","year":"2021","journal-title":"Intern Emerg Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1161\/circ.105.11.1278","article-title":"Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis","volume":"105","author":"Lim","year":"2002","journal-title":"Circulation."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/j.ijcard.2013.12.137","article-title":"Formation of the inflammasome in acute myocarditis","volume":"171","author":"Toldo","year":"2014","journal-title":"Int J Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1097\/CCM.0000000000001654","article-title":"Treating life-threatening myocarditis by blocking interleukin-1","volume":"44","author":"Cavalli","year":"2016","journal-title":"Crit Care Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1093\/rheumatology\/keaa207","article-title":"Antiarrhythmic efficacy of anakinra in a young patient with autoimmune lymphocytic myocarditis","volume":"59","author":"Bello","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"B48","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2459\/JCM.0000000000000989","article-title":"Fulminant myocarditis triggered by OC43 subtype coronavirus: a disease deserving evidence-based care bundles","volume":"21","author":"Veronese","year":"2020","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"B49","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.117.026386","article-title":"Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis","volume":"136","author":"Ammirati","year":"2017","journal-title":"Circulation."},{"key":"B50","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cjco.2020.10.017","article-title":"Effect of acute immunosuppression on left ventricular recovery and mortality in fulminant viral myocarditis: a case series and review of literature","volume":"3","author":"Turgeon","year":"2021","journal-title":"CJC Open."},{"key":"B51","doi-asserted-by":"publisher","first-page":"Itc81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11845-018-1934-7","article-title":"Cardiac manifestations of Han Chinese patients with systemic lupus erythematosus: a retrospective study","volume":"188","author":"Jia","year":"2019","journal-title":"Ir J Med Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1177\/0961203318770018","article-title":"Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies","volume":"27","author":"Tanwani","year":"2018","journal-title":"Lupus."},{"key":"B55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3899\/jrheum.160493","article-title":"Lupus myocarditis: initial presentation and longterm outcomes in a multicentric series of 29 patients","volume":"44","author":"Thomas","year":"2017","journal-title":"J Rheumatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/art.40792","article-title":"Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital enzyme-linked immunosorbent assay quantification of serum interferon-\u03b1","volume":"71","author":"Mathian","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10741-020-10054-w","article-title":"The spectrum of lupus myocarditis: from asymptomatic forms to cardiogenic shock","volume":"26","author":"Guglin","year":"2021","journal-title":"Heart Fail Rev."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJM199706263362603","article-title":"Idiopathic giant-cell myocarditis\u2013natural history and treatment. Multicenter giant cell myocarditis study group investigators","volume":"336","author":"Cooper","year":"1997","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: a population-based study","volume":"71","author":"Duarte-Garc\u00eda","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/jth.14798","article-title":"Antiphospholipid syndrome and the relationship between laboratory assay positivity and prevalence of non-bacterial thrombotic endocarditis: A retrospective cohort study","volume":"18","author":"Lenz","year":"2020","journal-title":"J Thromb Haemost."},{"key":"B65","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus."},{"key":"B66","doi-asserted-by":"publisher","first-page":"102292","DOI":"10.1016\/j.jaut.2019.06.003","article-title":"CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission","volume":"103","author":"Pineton de Chambrun","year":"2019","journal-title":"J Autoimmun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1161\/CIRCULATIONAHA.113.007417","article-title":"Myocardial catastrophe: a case of sudden, severe myocardial dysfunction","volume":"130","author":"Hucker","year":"2014","journal-title":"Circulation."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/art.27488","article-title":"Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study","volume":"62","author":"Sacr\u00e9","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.chest.2019.11.010","article-title":"In-hospital mortality-associated factors in patients with thrombotic antiphospholipid syndrome requiring ICU admission","volume":"157","author":"Pineton de Chambrun","year":"2020","journal-title":"Chest."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients","volume":"57","author":"Rodr\u00edguez-Pint\u00f3","year":"2018","journal-title":"Rheumatology (Oxford)."},{"key":"B71","doi-asserted-by":"publisher","first-page":"48","DOI":"10.14503\/THIJ-17-6472","article-title":"Catastrophic antiphospholipid syndrome presenting as congestive heart failure in a patient with thrombotic microangiopathy","volume":"46","author":"Tulai","year":"2019","journal-title":"Tex Heart Inst J."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10238-019-00565-8","article-title":"Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature","volume":"19","author":"Tinti","year":"2019","journal-title":"Clin Exp Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1016\/S1470-2045(20)30107-8","article-title":"Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research","volume":"21","author":"Johnson","year":"2020","journal-title":"Lancet Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e145186","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation."},{"key":"B81","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B82","doi-asserted-by":"publisher","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation."},{"key":"B85","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1161\/RES.0000000000000473","article-title":"Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the american heart association","volume":"129","author":"Asnani","year":"2021","journal-title":"Circ Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijcard.2019.07.025","article-title":"Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review","volume":"296","author":"Pradhan","year":"2019","journal-title":"Int J Cardiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijcard.2019.08.038","article-title":"Differences in clinical presentation and outcome between immune checkpoint inhibitor-associated myocarditis and classical acute myocarditis: Same disease, distinct challenges to face","volume":"296","author":"Veronese","year":"2019","journal-title":"Int J Cardiol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1161\/CIRCULATIONAHA.120.052307","article-title":"Mending broken hearts: a new treatment paradigm for immune checkpoint inhibitor-induced myocarditis","volume":"143","author":"Bermas","year":"2021","journal-title":"Circulation."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B93","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","article-title":"Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin","volume":"41","author":"Jain","year":"2018","journal-title":"J Immunother."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation."},{"key":"B96","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jacbts.2016.05.008","article-title":"21st century cardio-oncology: identifying cardiac safety signals in the era of personalized medicine","volume":"1","author":"Sheng","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMp1313140","article-title":"Cancer-drug discovery and cardiovascular surveillance","volume":"369","author":"Groarke","year":"2013","journal-title":"N Engl J Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"676","DOI":"10.6004\/jnccn.2021.0028","article-title":"Survivorship, Version 1","volume":"19","author":"Tevaarwerk","year":"2021","journal-title":"J Natl Compr Canc Netw."},{"key":"B100","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejca.2020.05.005","article-title":"Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand","volume":"135","author":"Patrinely","year":"2020","journal-title":"Eur J Cancer."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1056\/NEJMe1215300","article-title":"The cardiovascular perils of cancer survivorship","volume":"368","author":"Moslehi","year":"2013","journal-title":"N Engl J Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e007982","DOI":"10.1161\/CIRCHEARTFAILURE.120.007982","article-title":"Endothelial stromal PD-L1 (programmed death ligand 1) modulates CD8(+) T-cell infiltration after heart transplantation","volume":"14","author":"Bracamonte-Baran","year":"2021","journal-title":"Circ Heart Fail."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e008563","DOI":"10.1161\/CIRCHEARTFAILURE.121.008563","article-title":"PD-L1 (programmed death ligand 1) as a marker of acute cellular rejection after heart transplantation","volume":"14","author":"Choudhary","year":"2021","journal-title":"Circ Heart Fail."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/ejhf.2288","article-title":"Post-discharge arrhythmic risk stratification of patients with acute myocarditis and life-threatening ventricular tachyarrhythmias","volume":"23","author":"Gentile","year":"2021","journal-title":"Eur J Heart Fail."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jacc.2020.01.036","article-title":"Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation","volume":"75","author":"Peretto","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"e007520","DOI":"10.1161\/CIRCEP.119.007520","article-title":"Myocarditis causing premature ventricular contractions: insights from the MAVERIC Registry","volume":"12","author":"Lakkireddy","year":"2019","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation."},{"key":"B108","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.yjmcc.2020.08.008","article-title":"Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients","volume":"147","author":"Li","year":"2020","journal-title":"J Mol Cell Cardiol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.jacc.2021.03.006","article-title":"New heart failure diagnoses among patients hospitalized for COVID-19","volume":"77","author":"Alvarez-Garcia","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1001\/jamacardio.2021.2065","article-title":"Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry","volume":"6","author":"Daniels","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1161\/CIRCULATIONAHA.121.054824","article-title":"SARS-CoV-2 cardiac involvement in young competitive athletes","volume":"144","author":"Moulson","year":"2021","journal-title":"Circulation."},{"key":"B112","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamacardio.2021.0565","article-title":"Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening","volume":"6","author":"Martinez","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1161\/CIR.0000000000000455","article-title":"Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the american heart association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation."},{"key":"B114","doi-asserted-by":"publisher","first-page":"e007485","DOI":"10.1161\/CIRCHEARTFAILURE.120.007485","article-title":"Cardiogenic shock and hyperinflammatory syndrome in young males with COVID-19","volume":"13","author":"Chau","year":"2020","journal-title":"Circ Heart Fail."},{"key":"B115","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.chest.2020.08.2099","article-title":"Coronavirus disease 2019 Acute myocarditis and multisystem inflammatory syndrome in adult intensive and cardiac care units","volume":"159","author":"Hekimian","year":"2021","journal-title":"Chest."},{"key":"B116","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1093\/eurheartj\/ehaa664","article-title":"Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study","volume":"41","author":"Basso","year":"2020","journal-title":"Eur Heart J."},{"key":"B117","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/S2213-2600(21)00085-0","article-title":"Delayed-onset myocarditis following COVID-19","volume":"9","author":"Bajaj","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.120.050166","article-title":"Striking similarities of multisystem inflammatory syndrome in children and a myocarditis-like syndrome in adults: overlapping manifestations of COVID-19","volume":"143","author":"Most","year":"2021","journal-title":"Circulation."},{"key":"B119","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1161\/CIRCULATIONAHA.120.048360","article-title":"Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic","volume":"142","author":"Belhadjer","year":"2020","journal-title":"Circulation."},{"key":"B120","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10741-021-10087-9","article-title":"COVID-19 and myocarditis: a systematic review and overview of current challenges","volume":"27","author":"Castiello","year":"2022","journal-title":"Heart Fail Rev."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N Engl J Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after Covid-19 vaccination in a large health care organization","volume":"385","author":"Witberg","year":"2021","journal-title":"N Engl J Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.acvd.2021.06.001","article-title":"COVID-19 vaccines and myocarditis","volume":"114","author":"Kerneis","year":"2021","journal-title":"Arch Cardiovasc Dis."},{"key":"B127","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2006-02-004945","article-title":"Eosinophils are a major intravascular location for tissue factor storage and exposure","volume":"109","author":"Moosbauer","year":"2007","journal-title":"Blood."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1084\/jem.20161070","article-title":"Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease","volume":"214","author":"Uderhardt","year":"2017","journal-title":"J Exp Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/BF02536531","article-title":"Production of platelet-activating factor by human normodense and hypodense eosinophils","volume":"26","author":"Ojima-Uchiyama","year":"1991","journal-title":"Lipids."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2019000518","article-title":"Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps","volume":"134","author":"Marx","year":"2019","journal-title":"Blood."},{"key":"B131","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fmed.2017.00103","article-title":"Bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer","volume":"4","author":"Galdiero","year":"2017","journal-title":"Front Med (Lausanne)."},{"key":"B132","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nrrheum.2014.98","article-title":"Eosinophils in vasculitis: characteristics and roles in pathogenesis","volume":"10","author":"Khoury","year":"2014","journal-title":"Nat Rev Rheumatol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"6388","DOI":"10.1038\/s41598-021-85852-9","article-title":"Venous thrombosis and predictors of relapse in eosinophil-related diseases","volume":"11","author":"R\u00e9au","year":"2021","journal-title":"Sci Rep."},{"key":"B134","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1016\/j.jaip.2021.04.067","article-title":"Recurrent cardiac arrest due to eosinophilia-related coronary vasospasm successfully treated by benralizumab","volume":"9","author":"Groh","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B135","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.autrev.2019.06.004","article-title":"Distal ischemia as the initial presentation of hypereosinophilic syndrome-related arterial involvement: A case study and literature review","volume":"18","author":"Rohmer","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaip.2019.12.011","article-title":"\u201cIdiopathic eosinophilic vasculitis\u201d: another side of hypereosinophilic syndrome? A comprehensive analysis of 117 cases in asthma-free patients","volume":"8","author":"Lef\u00e8vre","year":"2020","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B137","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.jacc.2017.09.023","article-title":"Eosinophilic myocarditis: characteristics, treatment, and outcomes","volume":"70","author":"Brambatti","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2459\/JCM.0000000000000496","article-title":"The key clues to reach the diagnosis of Loeffler endomyocardial fibrosis associated with eosinophilic granulomatosis with polyangiitis","volume":"18","author":"Ammirati","year":"2017","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"B139","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/heartjnl-2020-317202","article-title":"Hypereosinophilic syndrome: considerations for the cardiologist","volume":"108","author":"Bondue","year":"2022","journal-title":"Heart."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.3389\/fonc.2019.01374","article-title":"B-ALL With t(5;14)(q31;q32); IGH-IL3 rearrangement and eosinophilia: a comprehensive analysis of a peculiar IGH-rearranged B-ALL","volume":"9","author":"Fournier","year":"2019","journal-title":"Front Oncol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1080\/1744666X.2016.1191352","article-title":"Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)","volume":"12","author":"Pagnoux","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2016.09.018","article-title":"Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"16","author":"Cottin","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jaip.2018.10.002","article-title":"C-Reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis","volume":"7","author":"Leurs","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B144","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.1161\/STROKEAHA.121.034191","article-title":"FIP1L1-PDGFRA-associated hypereosinophilic syndrome as a treatable cause of watershed infarction","volume":"52","author":"Tennenbaum","year":"2021","journal-title":"Stroke."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients","volume":"95","author":"Rohmer","year":"2020","journal-title":"Am J Hematol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S1473-3099(17)30331-6","article-title":"Human toxocariasis","volume":"18","author":"Ma","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"B148","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1182\/blood-2003-07-2393","article-title":"Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes","volume":"102","author":"Pitini","year":"2003","journal-title":"Blood."},{"key":"B149","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jaad.2013.01.032","article-title":"DRESS syndrome: Part II. Management and therapeutics","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/jamadermatol.2020.0048","article-title":"Evaluation of cyclosporine for the treatment of DRESS syndrome","volume":"156","author":"Nguyen","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jaip.2020.09.039","article-title":"Benralizumab for severe DRESS in two COVID-19 patients","volume":"9","author":"Schmid-Grendelmeier","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B152","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B156","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a european collaborative study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/hrt.79.4.362","article-title":"Long-term follow up of patients with endomyocardial fibrosis: effects of surgery","volume":"79","author":"Schneider","year":"1998","journal-title":"Heart."},{"key":"B160","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1097\/TP.0000000000000939","article-title":"Successful heart transplantation for unreversible endomyocardial fibrosis related to FIP1L1-PDGFRA chronic eosinophilic leukemia","volume":"99","author":"Fassnacht","year":"2015","journal-title":"Transplantation."},{"key":"B161","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.healun.2014.02.023","article-title":"Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)","volume":"33","author":"Groh","year":"2014","journal-title":"J Heart Lung Transplant."},{"key":"B162","doi-asserted-by":"publisher","first-page":"e007103","DOI":"10.1161\/CIRCHEARTFAILURE.120.007103","article-title":"Virome sequencing in patients with myocarditis","volume":"13","author":"Heidecker","year":"2020","journal-title":"Circ Heart Fail."},{"key":"B163","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/CIRCHEARTFAILURE.112.969261","article-title":"Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression","volume":"6","author":"Kandolin","year":"2013","journal-title":"Circ Heart Fail."},{"key":"B164","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCRESAHA.121.319317","article-title":"RNA-sequencing reveals a distinct transcriptomic signature for giant cell myocarditis and identifies novel druggable targets","volume":"129","author":"Amancherla","year":"2021","journal-title":"Circ Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"e019415","DOI":"10.1161\/JAHA.120.019415","article-title":"Manifestations and outcome of cardiac sarcoidosis and idiopathic giant cell myocarditis by 25-year nationwide cohorts","volume":"10","author":"Nordenswan","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jaccas.2020.05.107","article-title":"Biventricular intravascular microaxial blood pumps and immunosuppression as a bridge to recovery in giant cell myocarditis","volume":"2","author":"Ma","year":"2020","journal-title":"J Am Coll Cardiol Case Rep."},{"key":"B167","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.2459\/JCM.0000000000000250","article-title":"Giant cell myocarditis successfully treated with antithymocyte globuline and extracorporeal membrane oxygenation for 21 days","volume":"17","author":"Ammirati","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"B168","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijcard.2017.10.053","article-title":"Fulminant giant-cell myocarditis on mechanical circulatory support: Management and outcomes of a French multicentre cohort","volume":"253","author":"Montero","year":"2018","journal-title":"Int J Cardiol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jacc.2020.11.074","article-title":"Management of patients with giant cell myocarditis: JACC review topic of the week","volume":"77","author":"Bang","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cardfail.2017.04.015","article-title":"Heart transplantation in giant cell myocarditis: analysis of the united network for organ sharing registry","volume":"23","author":"Elamm","year":"2017","journal-title":"J Card Fail."},{"key":"B171","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jacc.2020.06.038","article-title":"Long-term adverse cardiac outcomes in patients with sarcoidosis","volume":"76","author":"Yafasova","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm."},{"key":"B173","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijcard.2021.04.022","article-title":"Identification of a novel presumed cardiac sarcoidosis category for patients at high risk of disease","volume":"335","author":"Rosenbaum","year":"2021","journal-title":"Int J Cardiol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/qjmed\/hcl038","article-title":"Presenting characteristics as predictors of duration of treatment in sarcoidosis","volume":"99","author":"Baughman","year":"2006","journal-title":"QJM."},{"key":"B175","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1161\/JAHA.115.003040","article-title":"Magnetic resonance imaging as a predictor of survival free of life-threatening arrhythmias and transplantation in cardiac sarcoidosis","volume":"5","author":"Ekstrom","year":"2016","journal-title":"J Am Heart Assoc."},{"key":"B176","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.amjcard.2015.06.021","article-title":"Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis","volume":"116","author":"Kandolin","year":"2015","journal-title":"Am J Cardiol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.cjca.2013.02.004","article-title":"Corticosteroid therapy for cardiac sarcoidosis: a systematic review","volume":"29","author":"Sadek","year":"2013","journal-title":"Can J Cardiol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Yazaki","year":"2001","journal-title":"Am J Cardiol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","article-title":"Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study","volume":"131","author":"Kandolin","year":"2015","journal-title":"Circulation."},{"key":"B180","first-page":"133","article-title":"Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block","volume":"20","author":"Kato","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/ejhf.1319","article-title":"Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres","volume":"20","author":"Fussner","year":"2018","journal-title":"Eur J Heart Fail."},{"key":"B182","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10554-005-9043-x","article-title":"Utility of gallium-67 scintigraphy for evaluation of cardiac sarcoidosis with ventricular tachycardia","volume":"22","author":"Futamatsu","year":"2006","journal-title":"Int J Cardiovasc Imaging."},{"key":"B183","doi-asserted-by":"publisher","first-page":"e010952","DOI":"10.1161\/JAHA.118.010952","article-title":"Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis","volume":"8","author":"Rosenthal","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J Clin Invest."},{"key":"B185","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijcard.2018.11.131","article-title":"Treatment of cardiac sarcoidosis: A comparative study of steroids and steroids plus immunosuppressive drugs","volume":"276","author":"Ballul","year":"2019","journal-title":"Int J Cardiol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs. azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest."},{"key":"B187","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3389\/fimmu.2013.00437","article-title":"Granuloma formation in pulmonary sarcoidosis","volume":"4","author":"Broos","year":"2013","journal-title":"Front Immunol."},{"key":"B188","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-\u03b1 inhibitors in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B189","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"B190","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J."},{"key":"B191","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B192","doi-asserted-by":"publisher","first-page":"12498","DOI":"10.1111\/joim.12498","article-title":"Infliximab in cardiac sarcoidosis","volume":"38","author":"Kandolin","year":"2017","journal-title":"Eur Heart J."},{"key":"B193","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.amjcard.2019.07.067","article-title":"Infliximab for refractory cardiac sarcoidosis","volume":"124","author":"Harper","year":"2019","journal-title":"Am J Cardiol."},{"key":"B194","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA."},{"key":"B195","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"B197","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ahj.2019.10.003","article-title":"Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT)","volume":"220","author":"Birnie","year":"2020","journal-title":"Am Heart J."},{"key":"B198","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.jacc.2020.08.012","article-title":"Inflammation as a predictor of recurrent ventricular tachycardia after ablation in patients with myocarditis","volume":"76","author":"Peretto","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijcard.2018.11.104","article-title":"Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis","volume":"280","author":"Peretto","year":"2019","journal-title":"Int J Cardiol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijcard.2017.11.032","article-title":"Cardiac magnetic resonance imaging in myocardial inflammation in autoimmune rheumatic diseases: An appraisal of the diagnostic strengths and limitations of the Lake Louise criteria","volume":"252","author":"Mavrogeni","year":"2018","journal-title":"Int J Cardiol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/heartjnl-2013-305187","article-title":"Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis","volume":"100","author":"Ise","year":"2014","journal-title":"Heart."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jcmg.2020.06.038","article-title":"Diagnostic applications of ultrasmall superparamagnetic particles of iron oxide for imaging myocardial and vascular inflammation","volume":"14","author":"Merinopoulos","year":"2021","journal-title":"JACC Cardiovasc Imaging."},{"key":"B204","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1161\/CIRCULATIONAHA.111.075283","article-title":"Noninvasive assessment of myocardial inflammation by cardiovascular magnetic resonance in a rat model of experimental autoimmune myocarditis","volume":"125","author":"Moon","year":"2012","journal-title":"Circulation."},{"key":"B205","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/heartjnl-2017-311688","article-title":"Ferumoxytol-enhanced magnetic resonance imaging in acute myocarditis","volume":"104","author":"Stirrat","year":"2018","journal-title":"Heart."},{"key":"B206","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","article-title":"JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis- digest version","volume":"83","author":"Terasaki","year":"2019","journal-title":"Circ J."},{"key":"B207","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ijcard.2016.11.142","article-title":"Serial FDG-PET scans help to identify steroid resistance in cardiac sarcoidosis","volume":"228","author":"Shelke","year":"2017","journal-title":"Int J Cardiol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cardfail.2019.02.018","article-title":"Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis","volume":"25","author":"Ning","year":"2019","journal-title":"J Card Fail."},{"key":"B209","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ehj.2004.02.002","article-title":"Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology","volume":"25","author":"Maisch","year":"2004","journal-title":"Eur Heart J."},{"key":"B210","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"B211","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2459\/JCM.0b013e328322f9b1","article-title":"Aetiological diagnosis in acute and recurrent pericarditis: when and how","volume":"10","author":"Imazio","year":"2009","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"B212","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ccl.2017.07.013","article-title":"Tuberculous and infectious pericarditis","volume":"35","author":"Chang","year":"2017","journal-title":"Cardiol Clin."},{"key":"B213","first-page":"487","article-title":"The heart matters: contribution of genetic factors in recurrent pericarditis","volume":"21","author":"Perricone","year":"2019","journal-title":"Isr Med Assoc J."},{"key":"B214","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4103\/ajm.AJM_78_17","article-title":"Cardiac manifestations of familial mediterranean fever","volume":"7","author":"Alsarah","year":"2017","journal-title":"Avicenna J Med."},{"key":"B215","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00296-017-3854-7","article-title":"Cardiovascular disease in patients with autoinflammatory syndromes","volume":"38","author":"Hintenberger","year":"2018","journal-title":"Rheumatol Int."},{"key":"B216","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00296-017-3853-8","article-title":"Cardiac disease in familial Mediterranean fever","volume":"38","author":"Erken","year":"2018","journal-title":"Rheumatol Int."},{"key":"B217","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2459\/JCM.0000000000000300","article-title":"Recurrent pericarditis in children and adolescents: a multicentre cohort study","volume":"17","author":"Imazio","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"B218","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12969-015-0057-1","article-title":"Relationship between clinical findings and genetic mutations in patients with familial Mediterranean fever","volume":"13","author":"Kilic","year":"2015","journal-title":"Pediatr Rheumatol Online J."},{"key":"B219","doi-asserted-by":"publisher","first-page":"8562485","DOI":"10.1155\/2020\/8562485","article-title":"Clinical features at onset and genetic characterization of pediatric and adult patients with TNF-\u03b1 receptor-associated periodic syndrome (TRAPS): A series of 80 cases from the AIDA network","volume":"2020","author":"Gaggiano","year":"2020","journal-title":"Mediators Inflamm."},{"key":"B220","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00247-019-04536-9","article-title":"Autoinflammatory diseases in childhood, part 1: monogenic syndromes","volume":"50","author":"Navallas","year":"2020","journal-title":"Pediatr Radiol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.semarthrit.2013.12.002","article-title":"The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up","volume":"43","author":"Cantarini","year":"2014","journal-title":"Semin Arthritis Rheum."},{"key":"B222","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00392-012-0422-8","article-title":"Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study","volume":"101","author":"Cantarini","year":"2012","journal-title":"Clin Res Cardiol."},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010128","article-title":"Diagnosis and management of the cryopyrin-associated periodic syndromes (CAPS): what do we know today?","volume":"10","author":"Welzel","year":"2021","journal-title":"J Clin Med."},{"key":"B224","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/1546-0096-11-S2-P189","article-title":"A novel mutation in the CIAS1\/NLRP3 gene associated with an unexpected phenotype of cryopyrin-associated periodic syndromes","volume":"32","author":"Insalaco","year":"2014","journal-title":"Clin Exp Rheumatol."},{"key":"B225","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ijcard.2004.06.012","article-title":"Recurrent idiopathic pericarditis: familial occurrence","volume":"102","author":"Brucato","year":"2005","journal-title":"Int J Cardiol."},{"key":"B226","doi-asserted-by":"publisher","first-page":"2002484","DOI":"10.1002\/advs.202002484","article-title":"The functional deubiquitinating enzymes in control of innate antiviral immunity","volume":"8","author":"Zong","year":"2021","journal-title":"Adv Sci (Weinh)."},{"key":"B227","doi-asserted-by":"publisher","first-page":"7206451","DOI":"10.1155\/2020\/7206451","article-title":"Nuclear alarmin cytokines in inflammation","volume":"2020","author":"Jiang","year":"2020","journal-title":"J Immunol Res."},{"key":"B228","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-981-13-9367-9_6","article-title":"Structural biology of NOD-like receptors","volume":"1172","author":"Yang","year":"2019","journal-title":"Adv Exp Med Biol."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/ijms22031048","article-title":"Advances in understanding activation and function of the NLRC4 inflammasome","volume":"22","author":"Sundaram","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B230","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.drudis.2021.02.018","article-title":"Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases","volume":"26","author":"Vong","year":"2021","journal-title":"Drug Discov Today."},{"key":"B231","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev."},{"key":"B232","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/1756-185X.13029","article-title":"Efficacy of anakinra in an adult patient with recurrent pericarditis and cardiac tamponade as initial manifestations of tumor necrosis factor receptor-associated periodic syndrome due to the R92Q TNFRSF1A variant","volume":"20","author":"Camprub\u00ed","year":"2017","journal-title":"Int J Rheum Dis."},{"key":"B233","first-page":"179","volume":"74","author":"Gawrysiak","year":"2017","journal-title":"Przegl Lek."},{"key":"B234","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/CRD.0000000000000358","article-title":"Cardiac manifestations of systemic lupus erythematous: an overview of the incidence, risk factors, diagnostic criteria, pathophysiology and treatment options","volume":"30","author":"Ward","year":"2022","journal-title":"Cardiol Rev."},{"key":"B235","doi-asserted-by":"publisher","first-page":"e4166","DOI":"10.7759\/cureus.4166","article-title":"Pericarditis in lupus","volume":"11","author":"Dein","year":"2019","journal-title":"Cureus."},{"key":"B236","doi-asserted-by":"publisher","first-page":"e000221","DOI":"10.1136\/lupus-2017-000221","article-title":"Associates and predictors of pleurisy or pericarditis in SLE","volume":"4","author":"Ryu","year":"2017","journal-title":"Lupus Sci Med."},{"key":"B237","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/j.amjmed.2019.07.038","article-title":"Recurrent pericarditis as an initial presentation of rheumatoid arthritis","volume":"133","author":"El Hasbani","year":"2020","journal-title":"Am J Med."},{"key":"B238","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.amjms.2020.10.012","article-title":"Recurrence of pericardial effusion after pericardiocentesis: does catheter-induced acute pericardial inflammation play a role?","volume":"361","author":"Lazaros","year":"2021","journal-title":"Am J Med Sci."},{"key":"B239","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11886-020-01308-y","article-title":"Novel pharmacotherapies for recurrent pericarditis: current options in 2020","volume":"22","author":"Tombetti","year":"2020","journal-title":"Curr Cardiol Rep."},{"key":"B240","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11739-021-02639-6","article-title":"Recurrent pericarditis: an update on diagnosis and management","volume":"16","author":"Andreis","year":"2021","journal-title":"Intern Emerg Med."},{"key":"B241","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s11739-019-02057-9","article-title":"Acute pericarditis or a systemic disease with pleuropulmonary involvement?","volume":"14","author":"Wu","year":"2019","journal-title":"Intern Emerg Med."},{"key":"B242","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11739-019-02041-3","article-title":"Clinical significance of pleural effusions and association with outcome in patients hospitalized with a first episode of acute pericarditis","volume":"14","author":"Lazaros","year":"2019","journal-title":"Intern Emerg Med."},{"key":"B243","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1714\/2922.29367","volume":"19","author":"Imazio","year":"2018","journal-title":"G Ital Cardiol."},{"key":"B244","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1136\/heartjnl-2018-314528","article-title":"Pericardial diseases in patients with hypothyroidism","volume":"105","author":"Chahine","year":"2019","journal-title":"Heart."},{"key":"B245","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11936-018-0654-7","article-title":"Pericardial disease in cancer patients","volume":"20","author":"Ghosh","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med."},{"key":"B246","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1136\/heartjnl-2018-313532","article-title":"Outcomes of idiopathic chronic large pericardial effusion","volume":"105","author":"Imazio","year":"2019","journal-title":"Heart."},{"key":"B247","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2021.10.005","article-title":"Prevalence and prognosis of pericardial effusion in patients affected by pectus excavatum: A case-control study","volume":"344","author":"Conte","year":"2021","journal-title":"Int J Cardiol."},{"key":"B248","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1053\/euhj.2002.3152","article-title":"Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy","volume":"23","author":"Maisch","year":"2002","journal-title":"Eur Heart J."},{"key":"B249","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1136\/heartjnl-2020-317966","article-title":"What is the normal composition of pericardial fluid?","volume":"107","author":"Buoro","year":"2021","journal-title":"Heart."},{"key":"B250","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccm.2012.11.006","article-title":"The Light criteria: the beginning and why they are useful 40 years later","volume":"34","author":"Light","year":"2013","journal-title":"Clin Chest Med."},{"key":"B251","doi-asserted-by":"publisher","first-page":"e13679","DOI":"10.1111\/eci.13679","article-title":"Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients","volume":"51","author":"Buckley","year":"2021","journal-title":"Eur J Clin Invest."},{"key":"B252","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/jama.2021.13443","article-title":"Myocarditis and pericarditis after vaccination for COVID-19","volume":"326","author":"Diaz","year":"2021","journal-title":"JAMA."},{"key":"B253","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1161\/CIRCULATIONAHA.110.986372","article-title":"Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis","volume":"123","author":"Imazio","year":"2011","journal-title":"Circulation."},{"key":"B254","doi-asserted-by":"publisher","first-page":"690","DOI":"10.2174\/1381612824666180116095658","article-title":"The role of colchicine in the treatment of autoinflammatory diseases","volume":"24","author":"Liantinioti","year":"2018","journal-title":"Curr Pharm Des."},{"key":"B255","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2013Update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum."},{"key":"B256","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/eurheartj\/ehn608","article-title":"Colchicine for pericarditis: hype or hope?","volume":"30","author":"Imazio","year":"2009","journal-title":"Eur Heart J."},{"key":"B257","first-page":"69","article-title":"Colchicine for the prevention of recurrent pericarditis","volume":"10","author":"Markel","year":"2008","journal-title":"Isr Med Assoc J."},{"key":"B258","doi-asserted-by":"publisher","first-page":"702","DOI":"10.2174\/1381612824666180116101823","article-title":"The role of colchicine in pericardial syndromes","volume":"24","author":"Lazaros","year":"2018","journal-title":"Curr Pharm Des."},{"key":"B259","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1056\/NEJMoa1208536","article-title":"A randomized trial of colchicine for acute pericarditis","volume":"369","author":"Imazio","year":"2013","journal-title":"N Engl J Med."},{"key":"B260","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7326\/0003-4819-155-7-201110040-00359","article-title":"Colchicine for recurrent pericarditis (CORP): a randomized trial","volume":"155","author":"Imazio","year":"2011","journal-title":"Ann Intern Med."},{"key":"B261","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/S0140-6736(13)62709-9","article-title":"Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial","volume":"383","author":"Imazio","year":"2014","journal-title":"Lancet."},{"key":"B262","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejphar.2004.07.011","article-title":"Effects of glucocorticoids on gene transcription","volume":"500","author":"Hayashi","year":"2004","journal-title":"Eur J Pharmacol."},{"key":"B263","first-page":"423","article-title":"A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate","volume":"91","author":"Sandborn","year":"1996","journal-title":"Am J Gastroenterol."},{"key":"B264","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ijcard.2011.01.027","article-title":"Azathioprine in isolated recurrent pericarditis: a single centre experience","volume":"147","author":"Vianello","year":"2011","journal-title":"Int J Cardiol."},{"key":"B265","doi-asserted-by":"publisher","first-page":"Cd001797","DOI":"10.1002\/14651858.CD001797.pub3","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"2013","author":"Eftimov","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B266","doi-asserted-by":"publisher","first-page":"Cd002063","DOI":"10.1002\/14651858.CD002063.pub6","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"2014","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"B267","doi-asserted-by":"publisher","first-page":"E327","DOI":"10.1002\/ajh.24404","article-title":"Difficulties in establishing the diagnosis of immune thrombocytopenia: An agreement study","volume":"91","author":"Salib","year":"2016","journal-title":"Am J Hematol."},{"key":"B268","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science."},{"key":"B269","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2459\/JCM.0000000000000260","article-title":"Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases","volume":"17","author":"Imazio","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"B270","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2459\/JCM.0000000000000266","article-title":"Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence","volume":"17","author":"Lazaros","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"B271","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: The AIRTRIP randomized clinical trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA."},{"key":"B272","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","article-title":"Pharmacokinetics of anakinra in subjects with different levels of renal function","volume":"74","author":"Yang","year":"2003","journal-title":"Clin Pharmacol Ther."},{"key":"B273","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00296-011-2096-3","article-title":"Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations","volume":"32","author":"Kaiser","year":"2012","journal-title":"Rheumatol Int."},{"key":"B274","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/14787210.2018.1483238","article-title":"Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs","volume":"16","author":"Goletti","year":"2018","journal-title":"Expert Rev Anti Infect Ther."},{"key":"B275","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/2047487319879534","article-title":"Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study","volume":"27","author":"Imazio","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"B276","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1177\/0091270009351882","article-title":"Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD)","volume":"50","author":"Radin","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"B277","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B278","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","article-title":"Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study","volume":"34","author":"Hoffman","year":"2012","journal-title":"Clin Ther."},{"key":"B279","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med."},{"key":"B280","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40261-013-0127-4","article-title":"Bioequivalence of canakinumab liquid pre-filled syringe and reconstituted lyophilized formulations following 150 mg subcutaneous administration: a randomized study in healthy subjects","volume":"33","author":"Chioato","year":"2013","journal-title":"Clin Drug Investig."},{"key":"B281","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody","volume":"51","author":"Chakraborty","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"B282","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s42358-020-0117-1","article-title":"Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant\/unresponsive familial Mediterranean fever","volume":"60","author":"Sahin","year":"2020","journal-title":"Adv Rheumatol."},{"key":"B283","first-page":"668","article-title":"Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups","volume":"36","author":"Feist","year":"2018","journal-title":"Clin Exp Rheumatol."},{"key":"B284","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/17512433.2017.1338946","article-title":"Pharmacological treatment options for cryopyrin-associated periodic syndromes","volume":"10","author":"Landmann","year":"2017","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B285","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/annrheumdis-2015-209031","article-title":"Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study","volume":"76","author":"Gattorno","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B286","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med."},{"key":"B287","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"B288","doi-asserted-by":"publisher","first-page":"167","DOI":"10.24953\/turkjped.2020.02.001","article-title":"Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases","volume":"62","author":"\u00c7akan","year":"2020","journal-title":"Turk J Pediatr."},{"key":"B289","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/rheumatology\/key077","article-title":"Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up","volume":"57","author":"Kougkas","year":"2018","journal-title":"Rheumatology (Oxford)."},{"key":"B290","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12969-020-00438-5","article-title":"Failure of anti Interleukin-1 \u03b2 monoclonal antibody in the treatment of recurrent pericarditis in two children","volume":"18","author":"Signa","year":"2020","journal-title":"Pediatr Rheumatol Online J."},{"key":"B291","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/eurheartj\/ehab724.1829","article-title":"Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic review and meta-analysis","volume":"27","author":"Imazio","year":"2021","journal-title":"Heart."},{"key":"B292","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1136\/heartjnl-2020-316898","article-title":"Anakinra for constrictive pericarditis associated with incessant or recurrent pericarditis","volume":"106","author":"Andreis","year":"2020","journal-title":"Heart."},{"key":"B293","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/ehjci\/jeu128","article-title":"European Association of Cardiovascular Imaging (EACVI) position paper: Multimodality imaging in pericardial disease","volume":"16","author":"Cosyns","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"B294","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/ehjci\/jeab131","article-title":"Role of non-invasive multimodality imaging in autoimmune pericarditis","volume":"22","author":"Jain","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"B295","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00330-005-0025-0","article-title":"Detection of pericardial inflammation with late-enhancement cardiac magnetic resonance imaging: initial results","volume":"16","author":"Taylor","year":"2006","journal-title":"Eur Radiol."},{"key":"B296","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.jcmg.2019.08.027","article-title":"Imaging-guided therapies for pericardial diseases","volume":"13","author":"Chetrit","year":"2020","journal-title":"JACC Cardiovasc Imaging."},{"key":"B297","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1161\/CIRCULATIONAHA.111.026070","article-title":"Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy: a pilot study","volume":"124","author":"Feng","year":"2011","journal-title":"Circulation."},{"key":"B298","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/eurheartj\/ehx629","article-title":"Diagnosis of active pericarditis by positron emission tomography (PET)\/cardiac magnetic resonance (CMR) imaging","volume":"39","author":"Xu","year":"2018","journal-title":"Eur Heart J."},{"key":"B299","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jacc.2016.11.059","article-title":"[(18)F]Fluorodeoxyglucose PET\/CT predicts response to steroid therapy in constrictive pericarditis","volume":"69","author":"Chang","year":"2017","journal-title":"J Am Coll Cardiol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.838564\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T01:48:02Z","timestamp":1646617682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.838564\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":299,"alternative-id":["10.3389\/fmed.2022.838564"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.838564","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"article-number":"838564"}}